Back to Market返回行情

ICLR ICON Public Limited Company

USHealthcare
$168.77+1.99%ClosedMarket Cap: $12.92B

As of 2026-07-09 16:00

Why ICLR matters now

ICON Public Limited Company (ICLR) is a US stock in Healthcare. The latest InvestLog snapshot shows $168.77 with +1.99% on the session and $12.92B in market capitalization; recent performance reads 1-month +28.58% and YTD -19.88%.

The latest financial table shown here is Q4 2025, with revenue of $2.11B, net income of $149.2M, and EPS of $1.93. Investors can compare that operating picture with valuation signals such as P/E 13.61 and FCF yield 12.0%.

The latest indexable market news headline is "INVESTOR ACTION NOTICE: Moore Law PLLC Encourages Investors in ICON plc (ICLR) to Contact Law Firm" from GlobeNewsWire.

Additional event context on this page matters because analyst consensus is Hold with a median target of $135.50; recent insider activity includes Elliott Jeffrey Thomas filing ; recent congressional disclosure data includes Kevin Hern Sale. These signals are research inputs, not a recommendation.

Valuation

P/E (TTM)

13.61

PEG

P/B

1.25

P/S

1.37

EV/EBITDA

10.84

DCF Value

$200.29

FCF Yield

12.0%

Div Yield

0.0%

Margins & Returns

Gross Margin

25.2%

Operating Margin

11.0%

Net Margin

6.0%

ROE

5.2%

ROA

3.0%

ROIC

6.0%

Financials

PeriodRevenueNet IncomeEPS
Q4 2025$2.11B$149.2M$1.93
FY 2025$8.25B$229.3M$2.90
Q3 2025$2.04B$2.4M$0.03
Q2 2025$2.02B$183.0M$2.30

Analyst Ratings

Consensus

Hold

Target (Consensus)

$139.90

Target (Median)

$135.50

Target Range

$100.00 - $216.00

Strong Buy: 0Buy: 8Hold: 8Sell: 0Strong Sell: 1
B of A SecuritiesUnderperform
2026-06-01
TD CowenBuy
2026-06-01
BMO CapitalOutperform
2026-05-29
BarclaysEqual Weight
2026-05-29
CitigroupNeutral
2026-05-29

Trading Activity

Insider Trades

Elliott Jeffrey Thomasdirector:
Sell2026-06-05
Egan Kevin Francisdirector:
Sell2026-06-05
McCague Eugene Pacellidirector
Sell2026-05-15
McCague Eugene Pacellidirector
Sell2026-05-15
CLIMAX JOHN DRdirector
Sell2026-05-15

Congress Trades

Kevin HernSell
2026-04-06
Julia LetlowSell
2026-03-13

Company Info

Sector

Healthcare

Industry

Medical - Diagnostics & Research

Country

IE

Exchange

Beta

1.27

ICON Public Limited Company operates as a global clinical research organization (CRO), delivering outsourced development and commercialization services across Ireland, continental Europe, the United States, and various other international regions. The firm excels in the strategic design, execution, and analytical oversight of programs that facilitate the entire spectrum of clinical trials, from initial compound identification through all phases (I-IV) of human studies. Its comprehensive suite of clinical development offerings encompasses early-stage drug development, strategies for patient enrollment and retention, strategic planning and data analysis, late-phase investigations, cutting-edge data and technology platforms, and expert consulting. Additionally, ICON provides specialized medical imaging, clinical research, and laboratory services; meticulous project management; efficient site monitoring and administration; robust data management; biostatistical analysis and programming; professional medical writing and publication support; medical affairs expertise; independent endpoint adjudication and data monitoring committee services; vigilant pharmacovigilance; interactive response technologies (IRT); streamlined clinical supplies logistics; strategic regulatory guidance; impactful medical communication; and broad advisory services. ICON's diverse clientele includes companies across the pharmaceutical, biotechnology, and medical device sectors, alongside governmental and public health bodies. Established in 1990, the company maintains its headquarters in Dublin, Ireland.